BEIJING, March 25 (Xinhua) -- Chinese Vice President Han Zheng met with John Swire & Sons Limited CEO Merlin Swire and Novartis CEO Vas Narasimhan on Monday in Beijing, who are here for the China ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

The company says it conducted a thorough evaluation of internal and external candidates, but decided that Vasant Narasimhan, known as Vas, was the best candidate to take the company forward.

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

As it stands, Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US, although Novartis chief executive Vas Narasimhan said this morning he ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

The news sparked a near-5% rise in Novartis’ share price. Chief executive Vas Narasimhan said performance was good “across all key growth brands and geographies” and “gives us continued ...

Novartis' chief executive, Vas Narasimhan, said that the licensing deal "bolsters our neuroscience pipeline and reflects our strategic focus and commitment to explore new and potentially ...